Weill David purchased $109K of TMDX

TransMedics Group (TMDX) and SoFi Technologies (SOFI) have seen significant stock declines. TMDX's revenue grew 21% YoY to $189.9M, but profits fell 52%. SOFI's revenue rose 43% to $1.2B, with net income up 61%. Both face near-term challenges but are seen as long-term opportunities.

TransMedics (NASDAQ: TMDX) shares fell about 8% after its Q2 results. The company reported 21% sales growth, but adjusted net income dropped from $35M in Q2 last year to $16M this year, below expectations. Management said about $19M of the change reflected spending on a next-gen kidney OCS, clinical programs, and a manufacturing plant in Italy.

TransMedics Group (Nasdaq: TMDX) reported Q2 2026 revenue of $189.9 million, up 21% year over year, with product revenue $111.2 million and service revenue $78.8 million. Net income was $14.7 million, or $0.41 per diluted share. The company raised full-year 2026 revenue guidance (excluding PAD Aviation) to $737 million to $757 million.

TransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TransMedics Reports Second Quarter 2026 Financial Results Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and

TheFly reported July 6 that Evercore ISI cut its TransMedics Group (TMDX) price target to $90 from $100 while keeping an Outperform rating, citing generally stable procedure volumes and capital spending trends. On the same day, TMDX said it will invest in PAD Aviation to expand its Organ Care System OCS program into Europe, aiming to improve organ access and transplant logistics.

NARAYEN SHANTANU (Chair and CEO) sold 125,000 indirectly-held shares of ADOBE INC. (ADBE) at an average of $250.76 ($246.09–$253.64, $31.34M total) across 12 trades over 2026-09-16 to 2026-09-17.